Sartorius AG (WBO:SRT3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:SRT3 Sartorius AG WBO:SRT3
78 GF Score
Price €244.20
GF Value €257.06
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Sartorius AG FFO?

FFO (Funds from operations) only applies to REITs.

WBO:SRT3
78GF Score
Sartorius AG WBO:SRT3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius AG (WBO:SRT3) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of €244.20 is trading 5% below its estimated GF Value™ of €257.06. GuruFocus considers Sartorius AG to be Fairly Valued.

Key valuation signals for WBO:SRT3:

  • FFO:
  • GF Value™: €257.06 vs. price of €244.20 (5% below fair value)
  • GF Score™: 78/100 with 10 warning signs

No single metric tells the full story. See the WBO:SRT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
78GF Score

Get the complete analysis for WBO:SRT3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€244.20
Price
€257.06
GF Value